Skip to main content
Erschienen in: Strahlentherapie und Onkologie 5/2014

01.05.2014 | Original article

Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips

verfasst von: I. Fortin, MD, MSc, J.-F. Carrier, PhD, M.-C. Beauchemin, MD, D. Béliveau-Nadeau, MSc, G. Delouya, MD, D. Taussky, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

The purpose of this work was to assess the stability of fiducial markers in the prostate bed and compared their use to surgical clips.

Patients and methods

In this study, 3–4 gold fiducial markers were transrectally implanted in the prostate bed of 14 patients. The stability of the fiducial markers position (fiducial markers fixity) over an EBRT course was assessed. Furthermore, the advantages of the fiducial markers compared to the surgical clips were assessed and the interobserver variation between the two technologies was compared.

Results

The mean fiducial marker migration during a course of EBRT was small with 1.2 mm (SD ± 0.8 mm). Compared to fiducial markers, the matches with surgical clips were mismatched ≥ 2 mm in 68 % of treatments. This discrepancy of > 2 mm was on average 3.7 ± 1.3 mm. There was less interobserver variability for matching of fiducial markers (0.8 ± 0.7 mm) than for surgical clips (2.0 ± 1.6 mm).

Conclusion

Fiducial markers showed less interobserver variability in matching and less variation in position than surgical clips. Fiducial markers could ultimately help in reducing treatment margins.
Literatur
1.
Zurück zum Zitat Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984PubMedCrossRef Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984PubMedCrossRef
2.
Zurück zum Zitat Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401PubMedCrossRef Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401PubMedCrossRef
3.
Zurück zum Zitat Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910–914PubMedCrossRef Roehl KA, Han M, Ramos CG et al (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910–914PubMedCrossRef
4.
Zurück zum Zitat Touijer K, Secin FP, Cronin AM et al (2009) Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol 55:1014–1019PubMedCentralPubMedCrossRef Touijer K, Secin FP, Cronin AM et al (2009) Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol 55:1014–1019PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Bolla M, Poppel H van, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef Bolla M, Poppel H van, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef
6.
Zurück zum Zitat Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962PubMedCentralPubMedCrossRef Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956–962PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRef Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRef
8.
Zurück zum Zitat Ost P, Cozzarini C, De Meerleer G et al (2011) High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 83:960–965PubMedCrossRef Ost P, Cozzarini C, De Meerleer G et al (2011) High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 83:960–965PubMedCrossRef
9.
Zurück zum Zitat Ost P, Lumen N, Goessaert AS et al (2011) High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 60:842–849PubMedCrossRef Ost P, Lumen N, Goessaert AS et al (2011) High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 60:842–849PubMedCrossRef
10.
Zurück zum Zitat Schiffner DC, Gottschalk AR, Lometti M et al (2007) Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 67:610–619PubMedCrossRef Schiffner DC, Gottschalk AR, Lometti M et al (2007) Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 67:610–619PubMedCrossRef
11.
Zurück zum Zitat Canter D, Greenberg RE, Horwitz EM et al (2010) Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. Can J Urol 17:5365–5369PubMed Canter D, Greenberg RE, Horwitz EM et al (2010) Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. Can J Urol 17:5365–5369PubMed
12.
Zurück zum Zitat Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385PubMedCrossRef Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385PubMedCrossRef
13.
Zurück zum Zitat Michalski JM, Lawton C, El Naqa I et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76:361–368PubMedCentralPubMedCrossRef Michalski JM, Lawton C, El Naqa I et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76:361–368PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Delouya G, Carrier JF, Beliveau-Nadeau D et al (2010) Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer. Radiother Oncol 96:43–47PubMedCrossRef Delouya G, Carrier JF, Beliveau-Nadeau D et al (2010) Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer. Radiother Oncol 96:43–47PubMedCrossRef
15.
Zurück zum Zitat Song S, Yenice KM, Kopec M, Liauw SL (2011) Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: a report of total setup error, required PTV expansion, and dosimetric implications. Radiother Oncol 103:270–274PubMedCrossRef Song S, Yenice KM, Kopec M, Liauw SL (2011) Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: a report of total setup error, required PTV expansion, and dosimetric implications. Radiother Oncol 103:270–274PubMedCrossRef
16.
Zurück zum Zitat Klayton T, Price R, Buyyounouski MK et al (2012) Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys 84:130–136PubMedCentralPubMedCrossRef Klayton T, Price R, Buyyounouski MK et al (2012) Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys 84:130–136PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Cavalieri R, Gay HA, Liu J et al (2011) Total error shift patterns for daily CT on rails image-guided radiotherapy to the prostate bed. Radiat Oncol 6:142PubMedCentralPubMedCrossRef Cavalieri R, Gay HA, Liu J et al (2011) Total error shift patterns for daily CT on rails image-guided radiotherapy to the prostate bed. Radiat Oncol 6:142PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Langenhuijsen JF, Donker R, McColl GM et al (2013) Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy: technique and complications rate. Strahlenther Onkol 189:476–481PubMedCrossRef Langenhuijsen JF, Donker R, McColl GM et al (2013) Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy: technique and complications rate. Strahlenther Onkol 189:476–481PubMedCrossRef
19.
Zurück zum Zitat Showalter TN, Nawaz AO, Xiao Y et al (2008) A cone beam CT-Based Study for clinical target definition using pelvic anatomy during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 70:431–436PubMedCrossRef Showalter TN, Nawaz AO, Xiao Y et al (2008) A cone beam CT-Based Study for clinical target definition using pelvic anatomy during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 70:431–436PubMedCrossRef
Metadaten
Titel
Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips
verfasst von
I. Fortin, MD, MSc
J.-F. Carrier, PhD
M.-C. Beauchemin, MD
D. Béliveau-Nadeau, MSc
G. Delouya, MD
D. Taussky, MD
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 5/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0631-3

Weitere Artikel der Ausgabe 5/2014

Strahlentherapie und Onkologie 5/2014 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Radiology in the Nazi era: part 1

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.